Pub Date : 2025-12-01DOI: 10.1001/jamadermatol.2025.3578
Elias A T Koch, Michael Sticherling, Nicola Wagner
{"title":"Pemphigus Foliaceous With Secondary Herpes Simplex Infection.","authors":"Elias A T Koch, Michael Sticherling, Nicola Wagner","doi":"10.1001/jamadermatol.2025.3578","DOIUrl":"10.1001/jamadermatol.2025.3578","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"1275-1276"},"PeriodicalIF":11.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145345295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1001/jamadermatol.2025.3537
Luiza Kalil, Brittany G Craiglow, Brett King
{"title":"Successful Treatment of Alopecia Areata With One JAK Inhibitor After Failure of Other JAK Inhibitors.","authors":"Luiza Kalil, Brittany G Craiglow, Brett King","doi":"10.1001/jamadermatol.2025.3537","DOIUrl":"10.1001/jamadermatol.2025.3537","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"1285-1287"},"PeriodicalIF":11.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12509074/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145251105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1001/jamadermatol.2025.3369
Yaelle Shaked, Alyssa Swearingen, Jennifer A Stein, David Polsky
{"title":"Navigating Melanoma In Situ in the Age of Overdiagnosis.","authors":"Yaelle Shaked, Alyssa Swearingen, Jennifer A Stein, David Polsky","doi":"10.1001/jamadermatol.2025.3369","DOIUrl":"10.1001/jamadermatol.2025.3369","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"1209-1210"},"PeriodicalIF":11.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145251093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1001/jamadermatol.2025.3928
Christopher Willy Schwarz, Mads Kirchheiner Rasmussen, Trine Bertelsen, Lars Iversen, Lone Skov, Nikolai Loft
{"title":"Comparative Cancer Risk in Patients With Psoriasis Treated With Adalimumab, Secukinumab, or Ustekinumab.","authors":"Christopher Willy Schwarz, Mads Kirchheiner Rasmussen, Trine Bertelsen, Lars Iversen, Lone Skov, Nikolai Loft","doi":"10.1001/jamadermatol.2025.3928","DOIUrl":"10.1001/jamadermatol.2025.3928","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"1289-1291"},"PeriodicalIF":11.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12547669/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145345291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1001/jamadermatol.2025.4072
Yi-Han Chang, John A McGrath, Chao-Kai Hsu
{"title":"Regression of Extensive Keloids During Imatinib Therapy for Gastrointestinal Stromal Tumor.","authors":"Yi-Han Chang, John A McGrath, Chao-Kai Hsu","doi":"10.1001/jamadermatol.2025.4072","DOIUrl":"10.1001/jamadermatol.2025.4072","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"1293-1294"},"PeriodicalIF":11.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145444800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1001/jamadermatol.2025.3512
Debby Cheng, Katherine Sanchez, Ursula Biba, Nora Bensellam, Sherry Ershadi, Samantha Gregoire, Yevgeniy R Semenov, Arash Mostaghimi, John S Barbieri, Nicholas Theodosakis
{"title":"Validating the Use of ICD-10 Codes for Identifying Vitiligo.","authors":"Debby Cheng, Katherine Sanchez, Ursula Biba, Nora Bensellam, Sherry Ershadi, Samantha Gregoire, Yevgeniy R Semenov, Arash Mostaghimi, John S Barbieri, Nicholas Theodosakis","doi":"10.1001/jamadermatol.2025.3512","DOIUrl":"10.1001/jamadermatol.2025.3512","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"1283-1284"},"PeriodicalIF":11.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12489791/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145199330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1001/jamadermatol.2025.4240
Chelsea N Campbell, Matthew S Krantz, Alexis Yu, Elizabeth J Phillips
<p><strong>Importance: </strong>Carriage of HLA-B*58:01 has been shown to be associated with allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS) in many populations globally; however, there is a critical need to investigate whether this is generalizable to populations of mixed ancestry, such as those in the US.</p><p><strong>Objective: </strong>To assess the association of human leukocyte antigen (HLA) class I and II in a cohort of US patients who received a diagnosis of allopurinol-induced SJS/TEN or DRESS compared with allopurinol-tolerant and population control participants.</p><p><strong>Design, setting, and participants: </strong>This genetic association study included consenting individuals who had specialist-adjudicated allopurinol-induced SJS/TEN or DRESS (collectively allopurinol-induced severe cutaneous adverse reactions [SCARs]) between January 1, 2015, and December 31, 2024. HLA carriage in these individuals was compared with allopurinol-tolerant and population control participants identified through the Vanderbilt University Medical Center biobank, which includes 94 489 individuals with imputed HLA class I and II typing from genotyping array data. Data were analyzed from January 2025 to August 2025.</p><p><strong>Main outcomes and measures: </strong>The main outcome measure was the association of HLA class I and II alleles with allopurinol-induced SCARs. HLA class I and II conditional logistic regression case-control analyses were performed between patients with allopurinol-induced SCARs and both population control and allopurinol-tolerant control participants matched on age, sex, and self-identified race. Odds ratios (ORs) and 95% CIs were reported, with Bonferroni-corrected P < .05.</p><p><strong>Results: </strong>This genetic association study used conditional logistic regression analyses and included 16 patients with allopurinol-induced SCAR (mean [SD] age, 61.1 [12.6] years; 9 female patients [56.25%] and 7 male patients [43.75%]) and 160 allopurinol-tolerant control participants matched 10:1. Two HLA class I alleles were found to be independently associated with increased risk of allopurinol-induced SCAR: HLA-B*58:01 (OR, 28.0 [95% CI, 8.6-100.6]) and HLA-A*34:02 (OR, 20.6 [95% CI, 3.3-131.1]). No HLA class II alleles meeting the Bonferroni-corrected P < .05 level of significance were identified.</p><p><strong>Conclusions and relevance: </strong>These findings suggest that although HLA-B*58:01 was found to be associated with allopurinol-induced SCARs, generalizing findings from previous studies, the allele was absent in more than one-third of the patient cohort and is therefore an incomplete indicator of risk. Importantly, in the US allopurinol-induced SCAR cohort, HLA-A*34:02 was found to be a second independent genetic risk factor for allopurinol-induced SCARs. These findings underscore the need to conduct population-based stud
重要性：在全球许多人群中，HLA-B*58:01的携带已被证明与别嘌呤醇诱导的史蒂文斯-约翰逊综合征和中毒性表皮坏死松解（SJS/TEN）以及嗜酸性粒细胞增多和全身症状（DRESS）的药物反应有关；然而，迫切需要调查这是否适用于混合血统的人群，比如美国人。目的：与别嘌呤醇耐受组和人群对照组比较，评估诊断为别嘌呤醇诱导的SJS/TEN或DRESS的美国患者中人类白细胞抗原（HLA） I类和II类的相关性。设计、环境和参与者：该遗传关联研究包括在2015年1月1日至2024年12月31日期间接受专家判定的别嘌呤醇诱导的SJS/TEN或DRESS（总别嘌呤醇诱导的严重皮肤不良反应[scar]）的同意个体。将这些人的HLA携带情况与范德比尔特大学医学中心生物银行鉴定的别嘌呤醇耐受者和人群对照者进行比较，其中包括94 489名从基因分型阵列数据中输入HLA I类和II类分型的个体。数据分析时间为2025年1月至2025年8月。主要结局和指标：主要结局指标是HLA I类和II类等位基因与别嘌呤醇诱导的疤痕的相关性。在别嘌呤醇诱导的疤痕患者与年龄、性别和种族匹配的人群对照组和别嘌呤醇耐受对照组之间进行HLA I类和II类条件logistic回归病例对照分析。结果：该遗传关联研究采用条件logistic回归分析，纳入了16例别嘌呤醇诱导的SCAR患者（平均[SD]年龄61.1[12.6]岁，9例女性患者[56.25%]，7例男性患者[43.75%]）和160例别嘌呤醇耐受对照患者（比例为10:1）。发现两个HLA I类等位基因与别嘌呤醇诱导的SCAR风险增加独立相关：HLA- b *58:01 （OR, 28.0 [95% CI, 8.6-100.6]）和HLA- a *34:02 （OR, 20.6 [95% CI, 3.3-131.1]）。结论和相关性：这些发现表明，尽管发现HLA- b *58:01与别嘌呤醇诱导的疤痕相关，但从以往的研究结果来看，该等位基因在超过三分之一的患者队列中缺失，因此是一个不完整的风险指标。重要的是，在美国别嘌呤醇诱导的SCAR队列中，HLA-A*34:02被发现是别嘌呤醇诱导的SCAR的第二个独立遗传危险因素。这些发现强调了开展基于人群的研究的必要性，这些研究既重现已知的HLA关联，又揭示新的HLA关联，从而通过筛查、风险分层和诊断来减少危害。
{"title":"HLA-B*58:01 and Risk of Allopurinol-Induced Severe Cutaneous Adverse Reactions in the US.","authors":"Chelsea N Campbell, Matthew S Krantz, Alexis Yu, Elizabeth J Phillips","doi":"10.1001/jamadermatol.2025.4240","DOIUrl":"10.1001/jamadermatol.2025.4240","url":null,"abstract":"<p><strong>Importance: </strong>Carriage of HLA-B*58:01 has been shown to be associated with allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS) in many populations globally; however, there is a critical need to investigate whether this is generalizable to populations of mixed ancestry, such as those in the US.</p><p><strong>Objective: </strong>To assess the association of human leukocyte antigen (HLA) class I and II in a cohort of US patients who received a diagnosis of allopurinol-induced SJS/TEN or DRESS compared with allopurinol-tolerant and population control participants.</p><p><strong>Design, setting, and participants: </strong>This genetic association study included consenting individuals who had specialist-adjudicated allopurinol-induced SJS/TEN or DRESS (collectively allopurinol-induced severe cutaneous adverse reactions [SCARs]) between January 1, 2015, and December 31, 2024. HLA carriage in these individuals was compared with allopurinol-tolerant and population control participants identified through the Vanderbilt University Medical Center biobank, which includes 94 489 individuals with imputed HLA class I and II typing from genotyping array data. Data were analyzed from January 2025 to August 2025.</p><p><strong>Main outcomes and measures: </strong>The main outcome measure was the association of HLA class I and II alleles with allopurinol-induced SCARs. HLA class I and II conditional logistic regression case-control analyses were performed between patients with allopurinol-induced SCARs and both population control and allopurinol-tolerant control participants matched on age, sex, and self-identified race. Odds ratios (ORs) and 95% CIs were reported, with Bonferroni-corrected P < .05.</p><p><strong>Results: </strong>This genetic association study used conditional logistic regression analyses and included 16 patients with allopurinol-induced SCAR (mean [SD] age, 61.1 [12.6] years; 9 female patients [56.25%] and 7 male patients [43.75%]) and 160 allopurinol-tolerant control participants matched 10:1. Two HLA class I alleles were found to be independently associated with increased risk of allopurinol-induced SCAR: HLA-B*58:01 (OR, 28.0 [95% CI, 8.6-100.6]) and HLA-A*34:02 (OR, 20.6 [95% CI, 3.3-131.1]). No HLA class II alleles meeting the Bonferroni-corrected P < .05 level of significance were identified.</p><p><strong>Conclusions and relevance: </strong>These findings suggest that although HLA-B*58:01 was found to be associated with allopurinol-induced SCARs, generalizing findings from previous studies, the allele was absent in more than one-third of the patient cohort and is therefore an incomplete indicator of risk. Importantly, in the US allopurinol-induced SCAR cohort, HLA-A*34:02 was found to be a second independent genetic risk factor for allopurinol-induced SCARs. These findings underscore the need to conduct population-based stud","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"1258-1263"},"PeriodicalIF":11.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12573116/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145389732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：